Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 StudiesNewsfile Corp • 11/08/24
Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis PigmentosaNewsfile Corp • 10/29/24
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 StudiesNewsfile Corp • 08/09/24
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal DystrophiesNewsfile Corp • 07/30/24
Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference PresentationNewsfile Corp • 07/10/24
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of DirectorsNewsfile Corp • 07/01/24
Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory BoardNewsfile Corp • 06/25/24
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal DiseaseNewsfile Corp • 05/10/24
Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences ConferenceNewsfile Corp • 05/08/24
Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis PigmentosaNewsfile Corp • 05/06/24
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation StudyNewsfile Corp • 04/11/24
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual MeetingNewsfile Corp • 03/28/24
Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal DiseasesNewsfile Corp • 03/25/24
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the EyeNewsfile Corp • 03/08/24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 MillionNewsfile Corp • 01/31/24
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in CliniNewsfile Corp • 01/31/24
Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis PigmentosaNewsfile Corp • 11/09/23
AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis PigmentosaNewsfile Corp • 11/04/23
Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor ConferenceNewsfile Corp • 10/16/23
Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis PigmentosaNewsfile Corp • 10/03/23
Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 YearsNewsfile Corp • 09/21/23
